Pardes Biosciences Inc. (PRDS)
Pardes Biosciences Statistics
Share Statistics
Pardes Biosciences has 62.01M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 62.01M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 14.06M |
| Failed to Deliver (FTD) Shares | 179.74K |
| FTD / Avg. Volume | 35.26% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.05 and the forward PE ratio is null. Pardes Biosciences's PEG ratio is 0.01.
| PE Ratio | -1.05 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/FCF Ratio | -1.36 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Pardes Biosciences has an Enterprise Value (EV) of 38.95M.
| EV / Sales | 0 |
| EV / EBITDA | -0.42 |
| EV / EBIT | -0.54 |
| EV / FCF | -0.54 |
Financial Position
The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.
| Current Ratio | 9.81 |
| Quick Ratio | 9.81 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -31.36 |
Financial Efficiency
Return on Equity is -51.86% and Return on Invested Capital is -53.57%.
| Return on Equity | -51.86% |
| Return on Assets | -46.58% |
| Return on Invested Capital | -53.57% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.64M |
| Employee Count | 57 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.18M |
| Effective Tax Rate | 3.29% |
Stock Price Statistics
The stock price has increased by 0.93% in the last 52 weeks. The beta is 0.42, so Pardes Biosciences's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | 0.93% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 70.03 |
| Average Volume (20 Days) | 509.69K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -99.82M |
| Net Income | -93.45M |
| EBITDA | -93.45M |
| EBIT | -93.45M |
| Earnings Per Share (EPS) | -1.61 |
Balance Sheet
The company has 59.28M in cash and 0 in debt, giving a net cash position of 59.28M.
| Cash & Cash Equivalents | 59.28M |
| Total Debt | 0 |
| Net Cash | 59.28M |
| Retained Earnings | -148.16M |
| Total Assets | 157.31M |
| Working Capital | 155.38M |
Cash Flow
In the last 12 months, operating cash flow was -71.98M and capital expenditures 0, giving a free cash flow of -71.98M.
| Operating Cash Flow | -71.98M |
| Capital Expenditures | 0 |
| Free Cash Flow | -71.98M |
| FCF Per Share | -1.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PRDS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -95.13% |
| FCF Yield | -73.27% |
Analyst Forecast
Currently there are no analyst rating for PRDS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 41.26 |
| Piotroski F-Score | 2 |